Lv51
988 积分 2023-11-24 加入
Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial
1小时前
已完结
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
12天前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
19天前
已完结
The immune microenvironment of colorectal cancer
1个月前
已完结
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
4个月前
已完结
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
5个月前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
6个月前
已完结
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
7个月前
已完结
SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
10个月前
已完结
皖公网安备34019202002308
